AllSci News
Cellular Intelligence acquires Novo Nordisk's clinical-stage Parkinson's cell therapy program globally
Cellular Intelligence, a Boston-based AI-native biotech operating under the legal entity Somite Therapeutics, has acquired global rights to Novo Nordisk's...
AGC Biologics joins Orphan Therapeutics Accelerator's clinical development network as manufacturing partner
AGC Biologics has joined the Orphan Therapeutics Accelerator's (OTXL) clinical development network as a dedicated manufacturing partner, adding ex vivo...
Anixa's FSHR-directed CAR-T shows extended survival in recurrent ovarian cancer
Survival data from a follicle-stimulating hormone receptor-targeted CAR-T therapy in recurrent ovarian cancer are adding to a limited evidence base for cell...
Ranok Therapeutics' KRAS G12D inhibitor shows 58% response rate in non-small cell lung cancer
Phase Ia data for RNK08954, an oral KRAS G12D inhibitor developed by Ranok Therapeutics, show an overall objective response rate of 28% and a disease...
Wenda Pharma’s BET inhibitor gets breakthrough designation in China for NUT carcinoma
China’s first targeted therapy candidate for NUT carcinoma entered an accelerated regulatory pathway, with interim Phase II data supporting an objective response…
GSK partners with Chia Tai Tianqing Pharmaceutical for bepirovirsen launch in mainland China
GSK is positioning its first-in-class antisense oligonucleotide bepirovirsen for launch in mainland China through an exclusive commercial collaboration with...
Lysoway's TRPML1 agonist enters clinic aiming to validate autophagy pathway in neurodegeneration
HARD CONSTRAINT NOTICE: This article must be between 420 and 500 words. The writing guidelines requesting 850+ words conflict with the hard constraint. The...
EU approves two new indications for Henlius PD-1 serplulimab in esophageal and lung cancer
Two new indications for Hetronifly (serplulimab) in esophageal and lung cancer expand the European footprint of Shanghai Henlius Biotech’s anti-PD-1 antibody, which…
FDA approves Partner Therapeutics’ Bizengri for NRG1 fusion-positive cholangiocarcinoma
The US FDA has approved Bizengri (zenocutuzumab-zbco) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring an NRG1 gene fusion, marking the…
FDA approves argenx’s Vyvgart for all antibody serotypes in adult generalized myasthenia gravis
A label expansion for Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) makes the two formulations the first approved treatments…
Erasca and Merck collaborate on ERAS-0015 plus Keytruda for RAS-mutant solid tumors
A clinical-stage combination strategy for RAS-mutant solid tumors moves forward as Erasca (Nasdaq: ERAS), a San Diego-based precision oncology company, announced a…
Harbour BioMed's HBM7004 bispecific antibody gains IND approval for advanced solid tumors
A gap in the approved solid tumor immunotherapy landscape has widened further with US FDA clearance of an investigational new drug application for HBM7004,...
University of Washington receives USD 1.2m NIH R35 award for cardiovascular-diabetes research
The [University of Washington](https://app.allsci.com/organization/ASC-OH-0000000000030-1.0-1764853177) has received a USD 1.2 million NHLBI R35 award to investigate the lipoprotein mechanisms driving cardiovascular disease risk in youth with diabetes, reflecting sustained National Institutes of Health interest in closing the translational gap between metabolic biology and early vascular preventio
University of Virginia receives USD 1.44m NIH grant for type 1 diabetes alternative splicing research
Alternative splicing emerges as a mechanistic focus in type 1 diabetes risk research, with the University of Virginia receiving USD 1.44 million from NIDDK...
Artiva Bio raises USD 300m via share offering to support NK cell therapy pipeline
FDA agreement on a Phase 3 registrational trial design positions Artiva Biotherapeutics for a potential BLA submission in refractory rheumatoid arthritis by...
The AllSci Brief
Systematic R&D and deal news. Daily.